New network enables community specialists to access the most innovative treatments opportunities, connects manufacturers to qualified patient populations for improved trial results
Valley Forge, PA – Today, IntrinsiQ Specialty Solutions and ION Solutions, both a part of AmerisourceBergen, announced the launch of AdvanceIQ Network, a resource designed to better match independent community oncology and urology practices with clinical trials and research opportunities. Through AdvanceIQ Network, these practices in the U.S. will have a more streamlined approach to identifying, qualifying for and enrolling in targeted clinical trials that offer groundbreaking treatment options for improved patient outcomes.
AdvanceIQ will be made available to more than 5,300 community specialty providers that are a part of ION Solutions and will help eliminate barriers that can prevent participation in clinical trials, including limited resources or time. Practices select the types of research in which they would like to participate, as well as provide access to de-identified patient information. Clinical trial developers can then leverage the AdvanceIQ Network to find practices treating patients who meet specific trial criteria. This offering not only enhances clinical trial matching and leverages new innovative trial recruitment solutions, but also increases patient access to the most advanced therapies and treatment strategies.
“The launch of AdvanceIQ Network addresses one of healthcare’s biggest challenges – access. As specialty care continues to grow, it’s critically important we create new pathways, through both innovation and partnerships, to connect patients to cutting-edge therapies found in clinical trials,” said Susan Weidner, Senior Vice President at IntrinsiQ Specialty Solutions.
AdvanceIQ Network will help to facilitate clinical trials, investigator research, prospective patient registries, retrospective outcomes research studies and panel studies. Participating practices and their physicians will also receive contract management resources, ongoing research education and training and grant submission support.
“We are constantly striving to provide exceptional support for patients, as well as providers, in order to drive better outcomes and ultimately enhance care,” said Vicki Albrecht, PhD, Senior Vice President and General Manager at ION Solutions. “By leveraging our expertise and network to connect our urology and oncology providers to new trials, AdvanceIQ can truly make an impact in supporting broader access to innovative research in a community setting.”
For more information about AdvanceIQ Network, please visit www.intrinsiq.com/advanceiq/.
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health. With over $145 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 19,000 people. AmerisourceBergen is ranked #12 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.